Biomarkers detection in blood with
high accuracy is crucial for
the diagnosis and treatment of many diseases. In this study, the proof-of-concept
fabrication of a dual-mode sensor based on a single probe (Re-BChE)
using a dual-signaling electrochemical ratiometric strategy and a
“turn-on” fluorescent method is presented. The probe
Re-BChE was synthesized in a single step and demonstrated dual mode
response toward butyrylcholinesterase (BChE), a promising biomarker
of Alzheimer’s disease (AD). Due to the specific hydrolysis
reaction, the probe Re-BChE demonstrated a turn-on current response
for BChE at −0.28 V, followed by a turn-off current response
at −0.18 V, while the fluorescence spectrum demonstrated a
turn-on response with an emission wavelength of 600 nm. The developed
ratiometric electrochemical sensor and fluorescence detection demonstrated
high sensitivity with BChE concentrations with a low detection limit
of 0.08 μg mL–1 and 0.05 μg mL–1, respectively. Importantly, the dual-mode sensor presents the following
advantages: (1) dual-mode readout can correct the impact of systematic
or background error, thereby achieving more accurate results; (2)
the responses of dual-mode readout originate from two distinct mechanisms
and relatively independent signal transduction, in which there is
no interference between two signaling routes. Additionally, compared
with the reported single-signal electrochemical assays for BChE, both
redox potential signals were detected in the absence of biological
interference within a negative potential window. Furthermore, it was
discovered that the outcomes of direct dual-mode electrochemical and
fluorescence quantifications of the level of BChE in serum were in
agreement with those obtained from the use of commercially available
assay kits for BChE sensing. This method has the potential to serve
as a useful point-of-care tool for the early detection of AD.